| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000459.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000459.txt","company":"Sionna Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000459.txt","article_chars":2822,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_c8b9a73e0dd3698e","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000459.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:29:23.743123+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000459.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000459.txt","source_event_id":"evt_56a279dce3e3","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"117f38bd56eee4dc","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-17","2026-04-18","2026-04-21","2006-03-27"],"entities":[{"asset_class":"equity","name":"Sionna Therapeutics, Inc.","relevance":"high","symbol":"SION","type":"issuer"},{"asset_class":"person","name":"Peter A. Thompson","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"fund","name":"OrbiMed Private Investments VIII, LP (OPI VIII)","relevance":"medium","symbol":"","type":"entity"},{"asset_class":"general_partner","name":"OrbiMed Capital GP VIII LLC (GP VIII)","relevance":"medium","symbol":"","type":"entity"},{"asset_class":"investment_adviser","name":"OrbiMed Advisors LLC (OrbiMed Advisors)","relevance":"medium","symbol":"","type":"entity"}],"event_type":"other","information_gaps":["The cleaned text does not explicitly label whether the listed common stock quantities/prices correspond to specific buy vs sell lines beyond the general statement that \u201cThese securities were sold pursuant to a 10b5-1 plan.\u201d","The filing\u2019s specific transaction type (e.g., number of shares sold vs other actions) is not fully structured in the provided text beyond the presence of quantities and prices.","No prior-state comparison details are provided in the signal beyond the fact that this is a \u201cdiscovery_sec_filing_delta\u201d; therefore, what changed vs prior known state cannot be determined from the provided text alone."],"key_facts":["SEC accession number: 0000947871-26-000459.","Form type: 4 (Form 4).","Issuer: Sionna Therapeutics, Inc. (SION).","Filed as of date: 2026-04-21.","Conformed period of report: 2026-04-17.","Reporting person: Peter A. Thompson (member of OrbiMed Advisors per disclosure).","The filing includes a statement: \u201cThese securities were sold pursuant to a 10b5-1 plan.\u201d","The filing includes relationship/beneficial ownership disclosures involving OPI VIII, GP VIII, and OrbiMed Advisors, including that certain persons disclaim beneficial ownership except to the extent of pecuniary interest.","The filing is signed: \u201c/s/ Peter A. Thompson\u201d with date 2026-04-21."],"numeric_claims":[{"label":"Conformed period of report","value":"20260417"},{"label":"Filed as of date","value":"20260421"},{"label":"Number of public documents","value":"1"},{"label":"Common stock transaction price (first listed)","value":"44.68"},{"label":"Common stock transaction price (second listed)","value":"44.52"},{"label":"Common stock quantity (first listed)","value":"52397"},{"label":"Common stock quantity (second listed)","value":"2948"}],"primary_claim":"Form 4 for Sionna Therapeutics, Inc. was filed on 2026-04-21 (covering 2026-04-17) by reporting person Peter A. Thompson, and the reported securities were sold pursuant to a 10b5-1 plan.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Sionna Therapeutics, Inc. (SION) filed an SEC Form 4 on 2026-04-21 covering transactions reported for the period ending 2026-04-17 by reporting person Peter A. Thompson. The filing states the securities were sold pursuant to a 10b5-1 plan and provides beneficial ownership/relationship disclosures tied to OrbiMed entities.","topics":["SEC Form 4","insider transaction","10b5-1 plan","OrbiMed ownership disclosures"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Sionna Therapeutics, Inc. \u00b7 Filed 20260421","ticker":"SION","tickers":["SION"],"title":"SION filed 4","url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000459.txt"}... |